术前β阻塞对PPGL患者手术结果的影响
相关实验视频
Updated: Jan 8, 2026

05:25
Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
1.2K
Marta Araujo-Castro1,2, Sara Donato3, Iñigo García Sanz4
1Endocrinology & Nutrition Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Endocrine-related cancer
|December 12, 2025
概括
在染细胞瘤和交感性偏瘤 (PPGL) 手术中的手术前β阻塞与更活跃的瘤有关. 在β-阻断剂患者的手术期间心律不整与氧胺的使用有关,而不是β-阻断剂本身.
科学领域:
- 内分泌学 在内分泌学.
- 手术瘤学手术瘤学
- 心血管外科心血管外科
背景情况:
- 乳红细胞瘤和交感性偏角细胞瘤 (PPGL) 是一种罕见的神经内分泌瘤.
- 最佳的管理涉及多学科的护理,包括手术切除.
- 术前β阻塞对PPGL手术结果的作用尚未得到充分证实.
研究的目的:
- 根据手术前使用β阻塞剂,分析PPGL患者手术内和术后并发症的差异.
- 研究接受α阻塞的PPGL患者的β阻塞和手术结果之间的关联.
主要方法:
- 对23所三级医院的390例PPGL切除进行了回顾性多中心研究.
- 患者被分为两组:接受了手术前β阻塞的患者和没有接受的患者.
- 进行了统计分析,包括多变量分析,以确定与并发症相关的因素.
主要成果:
- 在患有较高瘤活动标志物 (禁食血葡萄糖,血甲基内) 和较高阿尔法阻塞剂量的患者中,β阻塞更频繁.
- 用β阻塞预治疗的患者在手术前血压控制得更好 (70.7%vs59.1%).
- 在β阻塞组中观察到更高的手术期间心律失常率 (9.3%与3.7%相比),但在对α阻塞剂量进行调整后,这种差异减少了,并且独立地与氧胺使用和手术前心率降低有关.
结论:
- 在PPGL手术中,手术前的β阻塞在具有高度活跃瘤的患者中更为常见.
- 在接受β抑制剂治疗的患者中,手术期间心律不整的发病率增加似乎是因同时使用氧胺而不是β抑制剂本身而导致的.
- 这些发现表明,仔细选择α阻断剂可能对减轻PPGL手术中的手术内风险至关重要.
更多相关视频
相关概念视频
Cardiomyopathy VII: Pre and Post Operative Nursing Management
257
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
257
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.5K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.5K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Heart Failure Drugs: β-Blockers
729
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
729
Depolarizing Blockers: Pharmocokinetics
553
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
553

